Scarica l'app Stockscreener
6.59
0.60%
-0.04
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$6.63
Aprire:
$6.71
Volume 24 ore:
720.49K
Relative Volume:
0.41
Capitalizzazione di mercato:
$337.12M
Reddito:
-
Utile/perdita netta:
$-54.19M
Rapporto P/E:
-2.5543
EPS:
-2.58
Flusso di cassa netto:
$-37.34M
1 W Prestazione:
+14.81%
1M Prestazione:
+9.83%
6M Prestazione:
+26.25%
1 anno Prestazione:
+30.75%
Intervallo 1D:
$6.58
$6.92
Intervallo di 1 settimana:
$5.69
$6.92
Portata 52W:
$3.9328
$7.3236
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Nome
Abeona Therapeutics Inc
Settore
Industria
Telefono
646-813-4701
Indirizzo
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Confronta ABEO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
6.59 | 293.64M | 0 | -54.19M | -37.34M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-03-05 | Iniziato | Oppenheimer | Outperform |
| 2024-07-03 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-30 | Iniziato | Stifel | Buy |
| 2020-11-11 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-09-18 | Iniziato | B. Riley FBR | Buy |
| 2020-02-10 | Iniziato | SVB Leerink | Outperform |
| 2019-12-10 | Ripresa | Cantor Fitzgerald | Neutral |
| 2019-08-15 | Downgrade | Maxim Group | Buy → Hold |
| 2019-08-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2019-07-26 | Downgrade | Mizuho | Buy → Neutral |
| 2019-06-27 | Iniziato | Mizuho | Buy |
| 2018-10-12 | Iniziato | Mizuho | Buy |
| 2018-06-05 | Iniziato | Seaport Global Securities | Buy |
| 2017-11-08 | Iniziato | SunTrust | Buy |
| 2017-10-16 | Reiterato | H.C. Wainwright | Buy |
| 2017-10-11 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-10-10 | Iniziato | Citigroup | Buy |
| 2017-10-05 | Reiterato | Maxim Group | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-07-18 | Reiterato | Maxim Group | Buy |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2017-01-06 | Iniziato | Jefferies | Buy |
| 2016-09-29 | Reiterato | Maxim Group | Buy |
Mostra tutto
Abeona Therapeutics Inc Borsa (ABEO) Ultime notizie
What analysts say about Abeona Therapeutics Inc. stockExponential return rates - PrintWeekIndia
Abeona Therapeutics Inc. Stock Analysis and ForecastDynamic profit expansion - Autocar Professional
Abeona targets treating 10–14 ZEVASKYN patients in 2025 while securing $155M PRV sale to extend runway - MSN
What drives Abeona Therapeutics Inc. stock priceRapid market gains - Jammu Links News
Abeona Therapeutics Amends Loan Agreement with Avenue - TipRanks
Abeona Therapeutics lowers loan interest rate and issues warrants in loan amendment By Investing.com - Investing.com South Africa
Abeona Therapeutics lowers loan interest rate and issues warrants in loan amendment - Investing.com
Is Abeona Therapeutics Inc. a good long term investmentMarket-leading growth rates - Jammu Links News
Loss-Making Abeona Therapeutics Inc. (NASDAQ:ABEO) Set To Breakeven - simplywall.st
Abeona Therapeutics’ Gene Therapy Trial for MPS IIIA: A Promising Update - TipRanks
HC Wainwright Reiterates Buy Rating for Abeona Therapeutics (NASDAQ:ABEO) - MarketBeat
ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area - The Manila Times
Abeona Therapeutics Announces Activation of Lucile Packard Children’s Hospital Stanford as Qualified Treatment Center for FDA-Approved ZEVASKYN Therapy for RDEB - Quiver Quantitative
Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy - The Malaysian Reserve
Bio-Techne's Simple Western Enables Breakthrough FDA Approval for Rare Skin Disease Gene Therapy - Stock Titan
US FDA declines to approve Ultragenyx's gene therapy for rare genetic disorder - Reuters
(ABEO) Trading Report - news.stocktradersdaily.com
Abeona Therapeutics Executives Unload Massive Stock Holdings! - TipRanks
Farmer Mac (AGM) CFO Aparna Ramesh resigns; Gregory Ramsey named interim | ABEO SEC FilingForm 4 - Stock Titan
Abeona Therapeutics added to U.S. Small-cap Russell 2000 and Russell 3000 Indexes - MSN
Abeona sells Rare Pediatric Disease PRV for $155M - MSN
Abeona Therapeutics Sells Priority Review Voucher for $155M - The Globe and Mail
Abeona Therapeutics' PRV Sale: A Strategic Move to Fuel Gene Therapy Growth - AInvest
Abeona therapeutics closes sale of priority review voucher for $155 million - Investing.com
Abeona Therapeutics Gets $155 Million From Sale of FDA Priority Review Voucher; Shares Up Pre-Bell - MarketScreener
Abeona Therapeutics Inc. Closes $155 Million Sale of Rare Pediatric Disease Priority Review Voucher - Quiver Quantitative
Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million - The Manila Times
Abeona Therapeutics Announces Option Exercise by Beacon Therapeutics for Novel Aav204 Capsid for Ophthalmology Gene Therapy - MarketScreener
Beacon Therapeutics licenses Abeona’s AAV204 capsid for retinal therapies - Investing.com
Abeona Therapeutics® Announces Option Exercise by Beacon - GlobeNewswire
Beacon Therapeutics licenses Abeona’s AAV204 capsid for retinal therapies By Investing.com - Investing.com UK
Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index | ABEO Stock News - GuruFocus
Abeona Therapeutics Inc.(NasdaqCM: ABEO) added to Russell 3000E Growth Index - MarketScreener
Health Rounds: Inhaled insulin as good as injection for children at mealtime - Reuters
Abeona Therapeutics® Announces Publication in The Lancet of - GlobeNewswire
Abeona Therapeutics' Zevaskyn Vs. Krystal Biotech's Vyjuvek (KRYS, ABEO) - Seeking Alpha
Trend Tracker for (ABEO) - news.stocktradersdaily.com
ABEONA THERAPEUTICS Executives Sell Shares to Cover Tax Obligations - TradingView
Abeona Therapeutics Officer Sells Shares to Cover Tax Obligations - TradingView
Abeona Therapeutics Inc (NASDAQ:ABEO) Shares Purchased by Bank of America Corp DE - Defense World
Abeona Therapeutics: Substantially Undervalued Post-FDA Approval (Rating Upgrade) - Seeking Alpha
Abeona Therapeutics at Jefferies Conference: ZivaSkin’s Promising Launch By Investing.com - Investing.com Canada
Abeona Therapeutics (ABEO) Gains "Outperform" Rating from Oppenheimer | ABEO Stock News - GuruFocus
Abeona Therapeutics (ABEO) Gains Oppenheimer's Outperform Rating with Promising Outlook | ABEO Stock News - GuruFocus
Abeona Therapeutics (ABEO) Gains Oppenheimer's Outperform Rating - GuruFocus
Abeona Therapeutics (ABEO) Grants Equity Awards to New Employees - GuruFocus
Abeona Therapeutics Announces New Employee Inducement Grants - MarketScreener
Abeona Therapeutics (ABEO) Grants Equity Awards to New Employees | ABEO Stock News - GuruFocus
Abeona Therapeutics® Announces New Employee Inducement Grants Un - GuruFocus
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Abeona Therapeutics Awards Stock Grants Worth 11,500 Shares: New Employee Compensation Details Revealed - Stock Titan
Abeona Therapeutics Inc Azioni (ABEO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Abeona Therapeutics Inc Azioni (ABEO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Seshadri Vishwas | Chief Executive Officer |
Jul 09 '25 |
Sale |
5.86 |
69,420 |
406,503 |
1,234,341 |
| Vazzano Joseph Walter | Chief Financial Officer |
Jul 09 '25 |
Sale |
5.86 |
25,411 |
148,799 |
479,168 |
| Wuchterl Donald A. | Director |
Jul 08 '25 |
Sale |
5.82 |
5,176 |
30,147 |
145,436 |
| Charles Faith L. | Director |
Jul 09 '25 |
Sale |
5.86 |
10,738 |
62,879 |
139,094 |
| O'Malley Brendan M. | SVP, Chief Legal Officer |
Jul 09 '25 |
Sale |
5.86 |
17,428 |
102,053 |
360,817 |
| Alvino Mark | Director |
Jul 09 '25 |
Sale |
5.86 |
13,093 |
76,669 |
77,252 |
0.59%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):